OMER - omeros.com Market Value to Book Value Ratio
Omeros Corporation (OMER) maintains a high reputation for developing small-molecule compounds for the therapy of rare nervous system pathologies. The price trend confirms market interest, with the indicator standing at -26.67. The US business focuses on combating immune inflammation, leveraging successful late-stage trials. However, dependence on regulatory verdicts is increasing due to the concentration of assets within the biopharmaceutical segment.
Omeros Corporation (OMER) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization statistics:
- book capitalization data:
- debt and solvency information:
- earnings and valuation multiples indicators:
Comprehensive company analysis:Omeros Corporation
The high margins of Omeros Corporation (OMER) are driven by the specifics of the biotech industry, where colossal R&D expenditures translate into superprofits once patents are secured. By analyzing the current market-to-book ratio, an investor assesses the market value premium over net assets, which allows for determining the degree of asset overvaluation and identifying potential for speculative trades or long-term investment.
Analysis of competing companies
Biogen Inc. (BIIB) - Market Value to Book Value Ratio|neurocrine.com - Market Value to Book Value|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|Market Value to Book Value Ratio Amylyx Pharmaceuticals|Market-to-Book Ratio trevitherapeutics.com TRVI|Market Value to Book Value Ratio Praxis Precision Medicines, Inc. (PRAX)|Market Cap to Net Assets Ratio Anavex AVXL|Market Capitalization to Book Value Ratio CBLL (CeriBell Corp)|Prothena (PRTA) - Market-to-Book Ratio|ALEC - Market Value to Book Value Ratio|Market Value to Book Value ANNX (annexonbio.com)|Neurogene (NGNE) - Market Value to Book Value Ratio|Market-to-Book Ratio AC Immune S.A. (ACIU)|Market Value to Book Value Ratio Voyager Pharma|Neumora Corp (NMRA) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio SCLX (Scilex Holding Company)|TVGN (tevogen.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio ACOG (Alpha Cognition Inc.)|CGTX - Market Cap to Net Assets Ratio|IKT - Market Value to Book Value Ratio|Market-to-Book Ratio Cassava Pharma|assertiotx.com (ASRT) - Market Value to Book Value Ratio|Coya Therapeutics - Market Value to Book Value|Market Value to Book Value Ratio VistaGen Therapeutics, Inc.|Ovid Rx - Market Capitalization to Net Assets|Market Value to Book Value Ratio Acumen Pharma (ABOS)|CRVO - Market-to-Book Ratio|Market Value to Book Value Ratio Alterity Therapeutics Limited ATHE|Market Value to Book Value CLNN|PepGen Corp - Market Capitalization to Book Value Ratio|JUNS - Market Capitalization to Book Value Ratio|RLMD (Relmada) - Market Cap to Net Assets Ratio|ANVS: Market Cap to Book Value Multiple|GRCE (Grace Therapeutics Inc) - Market Capitalization to Book Value Ratio|fireflyneuro.com (AIFF) - Market Capitalization to Book Value|Market Value to Book Value Ratio Klotho Neurosciences Inc (KLTO)|NRSN - Market-to-Book Ratio|Market Value to Book Value Ratio Reviva Pharmaceuticals Holdings RVPH|MTVA: Capitalization to Book Value Ratio|NRXS - Market Value to Book Value Ratio|Market-to-Book Ratio Helius Medical|passagebio.com (PASG) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Neuphoria Therapeutics|NERV (Minerva Neurosciences Corp) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Athira Pharma Corp ATHA|Market Value to Book Value Ratio Addex Therapeutics (ADXN)|ALZN (alzamend.com) - Market Value to Book Value|Market Value to Book Value Ratio Cyclerion Therapeutics, Inc. CYCN|PTIX: Capitalization to Book Value Ratio|Pasithea - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Cortigent, Inc.|ATXI (Avenue Therapeutics) - Market Cap to Net Assets Ratio|brainstorm-cell.com (BCLI) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Cara Therapeutics|CHRO: Market Value to Book Value|Market Value to Book Value Ratio Eliem Therapeutics (ELYM)|ITCI - Market-to-Book Ratio|Market Value to Book Value Ratio Longboard Pharmaceuticals LBPH|marinuspharma.com (MRNS) - Market-to-Book Ratio|NKGN - Market Value to Book Value Ratio|NeuroBo Pharmaceuticals Inc (NRBO) - Market Cap to Net Assets Ratio|SAGE: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Synaptogenix, Inc (SNPX)|Market Value to Book Value Ratio Trevena, Inc.|VIGL: Market Value to Book Value|Market Value to Book Value Ratio Anew Medical, Inc. (WENA)|CERE - Market-to-Book Ratio